Department of Pathology, Stanford University School of Medicine, Stanford.
Merck Research Laboratories, Rahway, New Jersey.
Am J Surg Pathol. 2024 Nov 1;48(11):1395-1407. doi: 10.1097/PAS.0000000000002294. Epub 2024 Jul 19.
Ovarian serous borderline tumors (SBTs) have a generally favorable prognosis. Although the risk of progression to low-grade serous carcinoma is well documented, progression to high-grade carcinoma is rare. We report the clinicopathologic features of seven SBTs, each associated with the presence of a morphologically unique high-grade component with an extremely dismal prognosis. All of the SBTs exhibited typical hierarchical branching and scattered eosinophilic cells, whereas the high-grade component consisted of a profuse proliferation of epithelioid cells with abundant dense, eosinophilic cytoplasm, variable nuclear pleomorphism, and evident loss of WT1, estrogen receptor, and p16 positivity. In most cases, the SBT demonstrated an abrupt transition to the high-grade component, but one patient initially presented with the usual SBT and developed a recurrent disease that was composed entirely of the high-grade component. Targeted next-generation sequencing revealed identical driver mutations in both the SBT and high-grade components ( BRAF in 3, KRAS in 1), confirming clonality. Three cases, in addition, harbored telomerase reverse transcriptase promoter mutations in both components. One case, despite insufficient material for sequencing, was BRAF V600E-positive by immunohistochemistry. Most patients with available follow-up data died within 9 months of diagnosis. This study confirms prior reports of ovarian SBT transformation to high-grade carcinoma and further characterizes a distinct subset with abundant dense eosinophilic cytoplasm and an extremely dismal prognosis. The presence of BRAF mutations in a major subset of these tumors questions the notion that BRAF is associated with senescent eosinophilic cells and improved outcomes in SBT. The role of the additional telomerase reverse transcriptase promoter mutations merits further investigation.
卵巢浆液性交界性肿瘤 (SBT) 的预后通常较好。虽然向低级别浆液性癌进展的风险已有充分记录,但向高级别癌进展则较为罕见。我们报告了 7 例 SBT 的临床病理特征,每例均伴有形态独特的高级别成分,预后极差。所有 SBT 均表现出典型的分层分支和散在的嗜酸性细胞,而高级别成分则由大量上皮样细胞增生组成,具有丰富的密集嗜酸性细胞质、可变的核异型性和明显的 WT1、雌激素受体和 p16 阳性丧失。在大多数情况下,SBT 与高级别成分呈突然过渡,但 1 例患者最初表现为常见的 SBT,随后发生的复发性疾病完全由高级别成分组成。靶向下一代测序在 SBT 和高级别成分中均发现了相同的驱动突变 (3 例中的 BRAF,1 例中的 KRAS),证实了克隆性。此外,还有 3 例在两个成分中均存在端粒酶逆转录酶启动子突变。尽管有一个病例的组织材料不足,但免疫组织化学显示 BRAF V600E 阳性。大多数有随访数据的患者在诊断后 9 个月内死亡。本研究证实了先前关于卵巢 SBT 向高级别癌转化的报告,并进一步描述了一个具有丰富密集嗜酸性细胞质和极差预后的独特亚组。这些肿瘤的主要亚组中存在 BRAF 突变,这对 BRAF 与衰老的嗜酸性细胞和 SBT 中改善的结果相关的观点提出了质疑。额外的端粒酶逆转录酶启动子突变的作用值得进一步研究。